Balchem Corporation (BCPC)

From the record

Balchem Corporation's filings since 2017 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

From the record

Balchem Corporation's 10 filed years say what it did: revenue went from $553 million in fiscal 2016 to $1.0 billion in fiscal 2025, up 7.2% a year; it rose in 8 of 9 years; the deepest fall was 2% from fiscal 2022 to fiscal 2023; net income was positive in 10 of 10 of those years (its annual reports).

From the record

Over the 3 fiscal years to 2025-12-31, Balchem Corporation's diluted share count grew about 0.2% a year, and dividends and buybacks returned about 33% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 5 sales and 0 purchases of their own stock on the open market in the year to 2026-09-30 (their Form 4 filings).

From the record

Return on equity: in the fiscal year ended 2025-12-31, Balchem Corporation earned about 12 cents of profit for every dollar of shareholders' money, and gross profitability: its products earned about 22 cents per dollar of everything the company owns. Leverage: it owed about 25 cents per dollar of assets, and net share issuance: its share count shrank 0.3% over the year (the filed statements).

From the record

Balchem Corporation's standing among 15 graded names in its industry family: revenue of $1.0 billion in fiscal 2025 ranks in the bottom 46% by size; a net margin of 14.9% ranks in the top 3%; revenue growth of 3.2% a year over the last 3 filed years ranks in the top 17% (its annual reports).

From the record

Balchem Corporation's leadership, from its insiders' filings and its current reports: the chief executive on the record is Harris, Theodore L (Chairman, President & CEO, as filed), filing under that title since 2022-02-14, 4.7 years (top 37% of its family); most of the 17 officers and directors filing now have filed since the record of its people begins (2022-02-17), a floor of 4.7 years the record cannot see past, so that part is not read; 6 officer or director changes were reported on Form 8-K since 2023-11-13, against the 17 people in charge now (top 39%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Balchem Corporation's room to grow, from the newest filed statements (fiscal 2025): cash of $75 million against no long-term debt tagged leaves 4.4% of its assets as net cash, top 34% of its family; cash from operations less capital spending is 20.9% of revenue (top 17%); a gross margin of 35.7% (top 27%); research spending of 1.8% of revenue (bottom 14%) (its annual report).

From the record

Balchem Corporation's growth drivers, from the filed years to fiscal 2025: revenue grew 3.2% a year over the last three filed years against 7.2% over all 10, slowing (top 29% of its family); the newest year grew 8.8% (top 35%); research spending grew 14.9% a year (top 6%); capital spending grew 23.9% a year (top 27%) (its annual reports). Balchem Corporation reported 2 product lines in fiscal 2025: Product Sales at $1.0 billion (100%), Royalty at $2 million (0%); 2 of 2 grew against the year before (its annual report).

From the record

Balchem Corporation's newest year against its own record: revenue of $1.0 billion in fiscal 2025 came in 8.1% above the $959 million its prior three years' pace pointed to (bottom 38% of its family); net income of $155 million against a prior three-year average of $114 million (top 12%); a net margin of 14.9% against 12.1% before (top 29%) (its annual reports).